Selecting the Next Line of Therapy After SSA and PRRT in Progressive Pancreatic Neuroendocrine Tumor
This section focuses on the clinical decision making process following progression on lanreotide and lutetium Lu 177 dotatate. Dr Shaheen outlines how she approaches next line therapy selection in a ...
Moderators of Intervention Efficacy in the Pathways to Wellness Trial of Survivorship Education and Mindfulness Meditation for Younger Breast Cancer Survivors Patients with advanced, ...
Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to ...
Discuss theoretical and practical information on the biology, indications, diagnosis and current therapeutic options for the treatment of Neuroendocrine Tumors (NETS) Demonstrate a framework for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results